Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
Potent treatment options in ALK– and MET-positive disease - memoinOncology
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study — ALK POSITIVE
Progression-free survival by IRC Shown is the Kaplan-Meier curve for... | Download Scientific Diagram
Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence - Wang - 2022 - Cancer Medicine - Wiley Online Library
How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer
Cancers | Free Full-Text | Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - ScienceDirect
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial - The Lancet Oncology
ALK-positive NSCLC: updates on crizotinib and alectinib - memoinOncology
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - Annals of Oncology
Kaplan-Meier curve for overall survival after total follow-up of ALK+... | Download Scientific Diagram
A) Kaplan-Meier curve of progression-free survival (PFS) in the... | Download Scientific Diagram
EGFR- and ALK-targeted treatment: present and future - memoinOncology
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung
Changing Treatment Paradigm for ALK-Positive Lung Cancer - ILCN.org (ILCN/WCLC)
Natural History and Factors Associated with Overall Survival in Stage IV ALK‐Rearranged Non–Small Cell Lung Cancer | Semantic Scholar
Charu Aggarwal, MD, MPH on Twitter: "Final OS analysis of J-ALEX Alectinib vs Crizotinib ✴️ No significant OS difference BUT ✴️ Majority of patients crossed over to alectinib (~78%) @ALKLungCancer @alk_fusion @ASCO #
Stephen V Liu, MD on Twitter: "#ESMOAsia22 Survival is favoring alectinib for #ALK NSCLC over crizotinib, but not yet significant. Medians not reached and OS HR 0.60 overall with OS HR 0.40
Overall Survival Data: Primary & Exploratory 5-Year Landmark Analysis - ALECENSA® (alectinib)
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer - ScienceDirect
First-Line PFS - ALECENSA® (alectinib)
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Frontiers | Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib
Safety and effectiveness of alectinib in a real‐world surveillance study in patients with ALK‐positive non–small‐cell lung cancer in Japan - Masuda - 2019 - Cancer Science - Wiley Online Library
